CoChat

The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials

Open access
Liu, Ligang, Shi, Hekai, Xie, Merilyn, Sun, Yuxiao, Nahata, Milap C. · 2025 · Pharmaceuticals

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.

Abstract

Background: Obesity and type 2 diabetes (T2D) are major public health concerns. Tirzepatide has shown promise in recent clinical trials. This systematic review and meta-analysis aim to evaluate the efficacy and safety of tirzepatide in adults with obesity or type 2 diabetes, compared to placebo, GLP-1 receptor agonists (GLP-1 RAs), and insulin. Method: PubMed, Embase, and the Cochrane Library were searched on 17 January 2024, focusing on phase II and III randomized controlled trials (RCTs). We included studies involving adults with T2D or obesity, comparing tirzepatide to placebo, GLP-1 RAs, or insulin. The primary outcomes were the proportion of participants achieving ≥5%, ≥10%, and ≥15% weight loss targets. Secondary outcomes included changes in body weight, waist circumference, HbA1c levels, and blood pressure. Safety outcomes focused on adverse event rates. Meta-analyses were performed, and risk of bias was assessed using the Cochrane Risk-of-Bias tool version 2. Results: Fourteen RCTs involving 14,713 patients were included. Tirzepatide significantly increased the proportion of participants achieving weight loss targets, and reduced body weight, waist circumference, HbA1c, and blood pressure versus placebo and insulin. Compared with GLP-1 RAs, tirzepatide provided comparable or better outcomes in weight loss, waist circumference, and glycemic control. The incidence of gastrointestinal adverse events was significantly higher at all doses of tirzepatide compared to placebo and insulin. When compared with GLP-1 RAs, higher doses of tirzepatide were associated with increased risk of nausea, diarrhea, and decreased appetite, but not vomiting. Conclusions: Tirzepatide is an effective option for managing weight and improving metabolic outcomes in patients with T2D or obesity. However, it is associated with an increased risk of gastrointestinal adverse events, especially at higher doses. Therefore, close monitoring should be considered in clinical practice. Registration: PROSPERO CRD42021283449.

Overview

CoChat Summary

## TL;DR

This systematic review and meta-analysis of 14 randomized clinical trials (14,713 patients) found that tirzepatide improved weight, glycemic, and some blood-pressure outcomes in adults with type 2 diabetes and/or obesity. Benefits were strongest at higher doses, but adverse events and treatment discontinuation also increased, especially at 15 mg.

## Key findings

  • The review included 14 RCTs with 14,713 patients; 11 trials enrolled participants with diabetes and 3 focused on overweight/obesity without diabetes.
  • Compared with placebo, tirzepatide increased the proportion achieving at least 5%, 10%, and 15% weight loss; at 15 mg, the odds ratios were 16.82 for 5%, 12.20 for 10%, and 20.25 for 15% weight loss.
  • Tirzepatide reduced body weight, waist circumference, and HbA1c versus placebo, GLP-1 RAs, and insulin; for example, vs placebo, body weight SMDs were −1.05 (5 mg), −1.25 (10 mg), and −1.80 (15 mg), and HbA1c SMDs were −1.45, −1.59, and −1.56.
  • Safety tradeoff: any adverse events were higher at 5 mg and 15 mg vs placebo (OR 1.54 and 1.53), and treatment discontinuation due to adverse events increased with dose vs placebo (OR 1.76, 2.13, 2.92 for 5/10/15 mg).

## Methods

  • Systematic review and meta-analysis registered in PROSPERO (CRD42021283449) and reported per PRISMA.
  • Searched PubMed, Embase, and the Cochrane Library on 17 January 2024 for phase II/III randomized controlled trials in adults with type 2 diabetes or obesity/overweight with one health-related condition; comparators were placebo, GLP-1 RAs, or insulin.
  • Meta-analyses used R 4.0.3; continuous outcomes were summarized with SMDs and dichotomous outcomes with ORs, with subgroup analyses by comparator and tirzepatide dose (5, 10, 15 mg).

## Limitations

  • The paper states that GLP-1 RA doses were generally lower than approved therapeutic doses, which could affect comparative effectiveness.
  • The trial durations were relatively short, limiting conclusions about long-term efficacy and safety.
  • Many trials comparing tirzepatide with insulin or GLP-1 RAs were open-label, which may have introduced performance and detection bias, especially for subjective adverse-event outcomes.
  • All included studies were funded by Eli Lilly, and the authors note it is unclear whether this introduced reporting bias.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ph18050668

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Flow diagram of the selection process of studies.
Figure 1 Flow diagram of the selection process of studies.CC BY · PubMed Central

Verification

Claims the paper makes

7 Valid · 2 Not valid · 1 Not checked · 43 Own results and interpretations

18 more claims

Create a free account to see all 53 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 6
  • It may state two separate claims as one. 25
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Cited by

See all 19

Metadata

Authors
Liu, L., Shi, H., Xie, M., Sun, Y., & Nahata, M. C.
Affiliations
  • The Ohio State University (US)
  • Shanghai Medical College of Fudan University (CN)
  • St. John's University (US)
  • Sichuan University (CN)
Venue
Pharmaceuticals
Publisher
MDPI AG
Published
2025-04-30
Volume
18
Issue
5
Pages
668
ISSN
1424-8247 (ISSN-L)
OpenAlex
W4410029173
Cited by
19
References
50
Citations by year
2026: 13 · 2025: 6
FWCI
2.59
Type
journal article
Language
en
Open access
Locations
  • Pharmaceuticals (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
tirzepatide, type 2 diabetes, obesity, weight loss, GLP-1 receptor agonists, insulin, glycemic control, HbA1c, gastrointestinal adverse effects, drug safety, body weight, waist circumference, blood pressure

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.